Spectral Diagnostics (DIAGF) 0.3704 $DIAGF
Spectral Diagnostics and Toray Industries announce closing of Tranche "A" component of its up to $18.2 million Offering
CNW Group - Fri Jul 25, 8:26AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or"Spectral"
and Toray Industries, Inc. ("Toray" today announced the closing of Tranche "A" of the previously announced non-brokered private placement of the Corporation (the "Offering" . The Tranche "A" component of the Offering was comprised of 45,051,186 common shares of the Corporation ("Shares" ,at a subscription price of $0.293 per Share for aggregate proceeds of $13.2 million. The Offering was approved by shareholders of the Corporation at a special meeting of shareholders held on July 22, 2014.
Spectral Diagnostics announces shareholder approval of its up to $18.2 million offering
CNW Group - Tue Jul 22, 1:26PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or "Spectral" today announced that at the special meeting (the "Special Meeting" of shareholders ("Shareholders" of the Corporation held earlier today, Shareholders overwhelmingly approved the terms of the previously announced proposed non-brokered private placement of the Corporation of up to $18.2 million (the "Offering" .
Spectral Announces ISS and Glass Lewis Recommendations to Vote in Favour of its up to $18.2 Million Offering
CNW Group - Tue Jul 08, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or "Spectral" today announced that both ISS Proxy Advisory Services and Glass Lewis & Co. have endorsed the previously announced non-brokered private placement of the Corporation of up to $18.2 million (the "Proposed Offering" and recommend that shareholders of Spectral ("Shareholders" vote "FOR" the Proposed Offering at the upcoming special meeting of Shareholders to be held on July 22, 2014.
Spectral Diagnostics announces Proposed Offering of up to $18.2 million
CNW Group - Wed Jun 11, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" today announced it has entered into agreements for a non-brokered private placement of up to $18.2 million (the "Proposed Offering" .
U.S. FDA Approves Spectral's Amended Protocol for its EUPHRATES Trial
CNW Group - Tue Jun 03, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTCQX: DIAGF) ("Spectral" or the "Company" , a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that the U.S. Food and Drug Administration (FDA) has approved the amended protocol for its EUPHRATES trial, reflecting the recommendations of the Data Safety Monitoring Board (DSMB) of April 9, 2014. The DSMB recommended an additional exclusion criterion be added to the clinical protocol and that the sample size should be increased to 650 patients.
Point of Care Diagnostic Testing: World Markets - Updated 2014 Report (Includes 107 Company Profiles)
M2 - Thu May 15, 6:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nzmpts/point_of_care) has announced the addition of the "Point of Care Diagnostic Testing: World Markets" report to their offering. Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Companies Mentioned: - A. Menarini Diagnostics - ACON Laboratories, Inc. - Abaxis, Inc. - Abbott Laboratories - AccuBioTech Co., Ltd. - AccuTech, LLC - Accumetrics, Inc. (Accriva Diagnostics) - Beckman Coulter (Danaher Corporation) - BiOracle - Bio-Rad Laboratories, Inc. - BioLytical Laboratories - BioScan Screening Systems, Inc. - BioSite - Biomerica, Inc. - Calmark Sweden AB - s) - IND Diagnostic - Instrumentation Laboratory (IL)/Werfen Group - International Technidyne Corporation (ITC) - Jant Pharmacal Corporation - Johnson & Johnson - Lein Applied Diagnostics - Siloam Biosciences, Inc. - Spectral Diagnostics, Inc. - StatSure Diagnostic Systems, Inc. - Step Detect Associates, LLC - Strategic Diagnostics, Inc. - Techne Corporation - Telcare - Trinity Biotech Plc For more information visit http://www.researchandmarkets.com/research/nz...nt_of_care
Spectral announces first quarter, 2014 results
CNW Group - Thu May 15, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepis and septic shock, today announced its unaudited financial results for the first quarter ended March 31, 2014.
Spectral announces fourth quarter and fiscal 2013 results
CNW Group - Thu Mar 27, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepis and septic shock, today announced its audited financial results for the fourth quarter and year ended December 31, 2013.
Spectral Diagnostics Provides Clinical Update on the Euphrates Trial
CNW Group - Tue Mar 11, 4:00PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTCQX: DIAGF) ("Spectral" or the "Company" , a Phase III company developing the first theranostic treatment for patients with septic shock today announced an update on its ongoing EUPHRATES trial.
Spectral Diagnostics Announces Extension of Warrants
CNW Group - Mon Feb 24, 6:00AM CST
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" today announced that its board of directors has approved an extension of the expiry date of the outstanding 24,375,000 common share purchase warrants and 731,250 broker warrants of the Corporation (collectively, the "Warrants" from March 2, 2014 to September 2, 2014. The exercise price of the Warrants remains unamended at $0.60 and no other changes were made to the terms of the Warrants. The Warrants were issued in connection with a previous financing of the Corporation.
Spectral announces status of second interim analysis
CNW Group - Tue Jan 28, 6:00AM CST
Spectral Diagnostics Inc. (TSX:SDI) (OTCQX
IAGF) ("Spectral" or the "Company" , a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced that the Data Safety Monitoring Board (DSMB) has evaluated the safety, efficacy and futility of its EUPHRATES trial based on actual data for 184 randomized patients followed for 28 days.
2013 Report on the International High-Growth Diagnostic Testing Markets
M2 - Mon Jan 13, 7:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3946g5/highgrowth) has announced the addition of the "2013 Report on the International High-Growth Diagnostic Testing Markets" report to their offering. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. This examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned: - A Menarini Diagnostics - Bayer Corporation - Calypte Biomedical Corporation - Denka Seiken - EY Laboratories - Enterix - Genetix - Genzyme Diagnostics - Hologic Gen Probe - Instrumentation Laboratory - Jiangnan Biotech - Johnson & Johnson - Kyowa Medex - LifeAssays AB - LifeScan - Matritech - NOVA Biomedical - OraSure - Pheromone Sciences Corporation - QIAGEN NV - Radiometer Medical - Roche Diagnostics - Shanghai SIIC Kehua Biotech - Shionogi & Co - Siemens Healthcare Diagnostics - Spectral Diagnostics - Trinity Biotech - V?samed - diaDexus For more information visit http://www.researchandmarkets.com/research/3946g5/highgrowth
Spectral announces second quarter 2013 results
CNW Group - Tue Aug 13, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced its unaudited financial results for the second quarter ended June 30, 2013.
Spectral to present at Wedbush Life Sciences Conference
CNW Group - Thu Aug 01, 9:30AM CDT
Spectral Diagnostics Inc., (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced that the Company's President and CEO, Dr. Paul Walker, will be presenting a corporate overview at the Wedbush Life Sciences Management Access Conference in New York on Wednesday, August 14, 2013, at 1:20 p.m. ET.
Spectral provides update on its EUPHRATES trial
CNW Group - Wed Jul 31, 6:00AM CDT
- Trial is on track and continues to enroll patients at an accelerated rate -
Spectral Diagnostics Announces Board Changes
CNW Group - Fri Jul 26, 4:00PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" today announced that Mr. Ian Lennox and Mr. Ed McCormack have resigned as directors of the Corporation, effective August 1, 2013.
Spectral Diagnostics provides update on results of annual and special meeting
CNW Group - Thu May 23, 10:10PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" today announced that Mr. Anthony Bihl has been appointed as the Chairman of the board. The Corporation also notes that at the annual and special meeting of shareholders that was held earlier today, all eight nominees for the board were elected as a matter of corporate law, however, two of the directors received a greater number of votes withheld than votes in favour. Pursuant to the Majority Voting Policy of the Corporation, those two directors have each tendered their resignations as directors, effective only on acceptance by the board. Full details are contained in the Report of Voting Results for the Meeting which has been filed on Sedar at www.Sedar.com.
Spectral Appoints Vice President of Sales and Marketing
CNW Group - Tue May 07, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI / OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced the appointment of Dr. Gualtiero Guadagni as the Company's Vice President, Sales and Marketing.
Spectral Diagnostics adopts new By-Laws which contain advance notice provisions
CNW Group - Tue Apr 16, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) ("Spectral", or the "Corporation" today announced the approval and adoption by its board of directors (the "Board" of new by-laws ("By-Laws" which include advance notice provisions, the purpose of which is to require advance notice be provided to the Corporation in circumstances where nominations of persons for election to the Board are made by shareholders of the Corporation other than pursuant to: (i) a requisition of a meeting of shareholders made pursuant to the provisions of the Business Corporations Act (Ontario) (the "Act" ; or (ii) a shareholder proposal made pursuant to the provisions of the Act.
Spectral Diagnostics and Toray Industries announce closing of Tranche "A" component of its up to $18.2 million Offering
CNW Group - Fri Jul 25, 8:26AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or"Spectral"
and Toray Industries, Inc. ("Toray" today announced the closing of Tranche "A" of the previously announced non-brokered private placement of the Corporation (the "Offering" . The Tranche "A" component of the Offering was comprised of 45,051,186 common shares of the Corporation ("Shares" ,at a subscription price of $0.293 per Share for aggregate proceeds of $13.2 million. The Offering was approved by shareholders of the Corporation at a special meeting of shareholders held on July 22, 2014. Spectral Diagnostics announces shareholder approval of its up to $18.2 million offering
CNW Group - Tue Jul 22, 1:26PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or "Spectral"
today announced that at the special meeting (the "Special Meeting" of shareholders ("Shareholders" of the Corporation held earlier today, Shareholders overwhelmingly approved the terms of the previously announced proposed non-brokered private placement of the Corporation of up to $18.2 million (the "Offering" . Spectral Announces ISS and Glass Lewis Recommendations to Vote in Favour of its up to $18.2 Million Offering
CNW Group - Tue Jul 08, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation" or "Spectral"
today announced that both ISS Proxy Advisory Services and Glass Lewis & Co. have endorsed the previously announced non-brokered private placement of the Corporation of up to $18.2 million (the "Proposed Offering" and recommend that shareholders of Spectral ("Shareholders" vote "FOR" the Proposed Offering at the upcoming special meeting of Shareholders to be held on July 22, 2014. Spectral Diagnostics announces Proposed Offering of up to $18.2 million
CNW Group - Wed Jun 11, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation"
today announced it has entered into agreements for a non-brokered private placement of up to $18.2 million (the "Proposed Offering" . U.S. FDA Approves Spectral's Amended Protocol for its EUPHRATES Trial
CNW Group - Tue Jun 03, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTCQX: DIAGF) ("Spectral" or the "Company"
, a Phase III company developing the first theranostic treatment for patients with septic shock, today announced that the U.S. Food and Drug Administration (FDA) has approved the amended protocol for its EUPHRATES trial, reflecting the recommendations of the Data Safety Monitoring Board (DSMB) of April 9, 2014. The DSMB recommended an additional exclusion criterion be added to the clinical protocol and that the sample size should be increased to 650 patients. Point of Care Diagnostic Testing: World Markets - Updated 2014 Report (Includes 107 Company Profiles)
M2 - Thu May 15, 6:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nzmpts/point_of_care) has announced the addition of the "Point of Care Diagnostic Testing: World Markets" report to their offering. Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening. Key Topics Covered: 1. Overview 2. Overview of Diagnostic Testing Point of Care Markets 3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share 7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 8. Review of the Market Segments, Reagents and Equipment 9. POCT: Growth Regulators 10. Business Trends in the POC Sector 11. Technology Platform Innovations in POCT 12. Data Management and Connectivity 13. Corporate Profiles 14. POCT Sector Trends and Forecasts 15. New Entrants to the Point of Care Market Companies Mentioned: - A. Menarini Diagnostics - ACON Laboratories, Inc. - Abaxis, Inc. - Abbott Laboratories - AccuBioTech Co., Ltd. - AccuTech, LLC - Accumetrics, Inc. (Accriva Diagnostics) - Beckman Coulter (Danaher Corporation) - BiOracle - Bio-Rad Laboratories, Inc. - BioLytical Laboratories - BioScan Screening Systems, Inc. - BioSite - Biomerica, Inc. - Calmark Sweden AB - s) - IND Diagnostic - Instrumentation Laboratory (IL)/Werfen Group - International Technidyne Corporation (ITC) - Jant Pharmacal Corporation - Johnson & Johnson - Lein Applied Diagnostics - Siloam Biosciences, Inc. - Spectral Diagnostics, Inc. - StatSure Diagnostic Systems, Inc. - Step Detect Associates, LLC - Strategic Diagnostics, Inc. - Techne Corporation - Telcare - Trinity Biotech Plc For more information visit http://www.researchandmarkets.com/research/nz...nt_of_care
Spectral announces first quarter, 2014 results
CNW Group - Thu May 15, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepis and septic shock, today announced its unaudited financial results for the first quarter ended March 31, 2014.
Spectral announces fourth quarter and fiscal 2013 results
CNW Group - Thu Mar 27, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepis and septic shock, today announced its audited financial results for the fourth quarter and year ended December 31, 2013.
Spectral Diagnostics Provides Clinical Update on the Euphrates Trial
CNW Group - Tue Mar 11, 4:00PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTCQX: DIAGF) ("Spectral" or the "Company"
, a Phase III company developing the first theranostic treatment for patients with septic shock today announced an update on its ongoing EUPHRATES trial. Spectral Diagnostics Announces Extension of Warrants
CNW Group - Mon Feb 24, 6:00AM CST
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation"
today announced that its board of directors has approved an extension of the expiry date of the outstanding 24,375,000 common share purchase warrants and 731,250 broker warrants of the Corporation (collectively, the "Warrants" from March 2, 2014 to September 2, 2014. The exercise price of the Warrants remains unamended at $0.60 and no other changes were made to the terms of the Warrants. The Warrants were issued in connection with a previous financing of the Corporation. Spectral announces status of second interim analysis
CNW Group - Tue Jan 28, 6:00AM CST
Spectral Diagnostics Inc. (TSX:SDI) (OTCQX
IAGF) ("Spectral" or the "Company" , a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced that the Data Safety Monitoring Board (DSMB) has evaluated the safety, efficacy and futility of its EUPHRATES trial based on actual data for 184 randomized patients followed for 28 days. 2013 Report on the International High-Growth Diagnostic Testing Markets
M2 - Mon Jan 13, 7:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3946g5/highgrowth) has announced the addition of the "2013 Report on the International High-Growth Diagnostic Testing Markets" report to their offering. Clinical labs experienced a substantial growth during the last decade. The emphasis in this report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. This examination provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category. Key Topics Covered: 1. Overview 2. Introduction to the High-Growth Testing Market 3. Hepatitis Serologic Markers and Nucleic Acid Testing 4. Human Papillomavirus (HPV) Testing 5. HIV 6. Infectious Disease Testing 7. Cardiac Markers 8. Cytogenetic Testing 9. Fertility Testing 10. Cancer Biomarker Testing 11. Substance Abuse Testing 12. Vitamin D Diagnostic Testing 13. Renal Dialysis Testing 14. Companion Diagnostics 15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region 16. Clinical Laboratory Genomics 17. Cellular Imaging Cytopathology and Histopathology 18. High-Growth Testing Diagnostic Trends 19. Important Technology Trends 20. Molecular Diagnostics a Major Diagnostic Technological Advance 21. Technology Platform Innovations in POCT 22. Data Management and Connectivity 23. Biochips for Clinical Applications 24. Company Profiles Companies Mentioned: - A Menarini Diagnostics - Bayer Corporation - Calypte Biomedical Corporation - Denka Seiken - EY Laboratories - Enterix - Genetix - Genzyme Diagnostics - Hologic Gen Probe - Instrumentation Laboratory - Jiangnan Biotech - Johnson & Johnson - Kyowa Medex - LifeAssays AB - LifeScan - Matritech - NOVA Biomedical - OraSure - Pheromone Sciences Corporation - QIAGEN NV - Radiometer Medical - Roche Diagnostics - Shanghai SIIC Kehua Biotech - Shionogi & Co - Siemens Healthcare Diagnostics - Spectral Diagnostics - Trinity Biotech - V?samed - diaDexus For more information visit http://www.researchandmarkets.com/research/3946g5/highgrowth
Spectral announces second quarter 2013 results
CNW Group - Tue Aug 13, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced its unaudited financial results for the second quarter ended June 30, 2013.
Spectral to present at Wedbush Life Sciences Conference
CNW Group - Thu Aug 01, 9:30AM CDT
Spectral Diagnostics Inc., (TSX: SDI) (OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced that the Company's President and CEO, Dr. Paul Walker, will be presenting a corporate overview at the Wedbush Life Sciences Management Access Conference in New York on Wednesday, August 14, 2013, at 1:20 p.m. ET.
Spectral provides update on its EUPHRATES trial
CNW Group - Wed Jul 31, 6:00AM CDT
- Trial is on track and continues to enroll patients at an accelerated rate -
Spectral Diagnostics Announces Board Changes
CNW Group - Fri Jul 26, 4:00PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation"
today announced that Mr. Ian Lennox and Mr. Ed McCormack have resigned as directors of the Corporation, effective August 1, 2013. Spectral Diagnostics provides update on results of annual and special meeting
CNW Group - Thu May 23, 10:10PM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) (the "Corporation"
today announced that Mr. Anthony Bihl has been appointed as the Chairman of the board. The Corporation also notes that at the annual and special meeting of shareholders that was held earlier today, all eight nominees for the board were elected as a matter of corporate law, however, two of the directors received a greater number of votes withheld than votes in favour. Pursuant to the Majority Voting Policy of the Corporation, those two directors have each tendered their resignations as directors, effective only on acceptance by the board. Full details are contained in the Report of Voting Results for the Meeting which has been filed on Sedar at www.Sedar.com. Spectral Appoints Vice President of Sales and Marketing
CNW Group - Tue May 07, 6:00AM CDT
Spectral Diagnostics Inc., (TSX:SDI / OTCQX: DIAGF), a Phase III company developing the first theranostic treatment for patients with septic shock, today announced the appointment of Dr. Gualtiero Guadagni as the Company's Vice President, Sales and Marketing.
Spectral Diagnostics adopts new By-Laws which contain advance notice provisions
CNW Group - Tue Apr 16, 6:00AM CDT
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX: DIAGF) ("Spectral", or the "Corporation"
today announced the approval and adoption by its board of directors (the "Board" of new by-laws ("By-Laws" which include advance notice provisions, the purpose of which is to require advance notice be provided to the Corporation in circumstances where nominations of persons for election to the Board are made by shareholders of the Corporation other than pursuant to: (i) a requisition of a meeting of shareholders made pursuant to the provisions of the Business Corporations Act (Ontario) (the "Act" ; or (ii) a shareholder proposal made pursuant to the provisions of the Act. 
